Can the efficacy of a medical treatment be predicted based on the type of idiopathic premature ventricular contraction?

J Electrocardiol. 2024 Sep-Oct:86:153782. doi: 10.1016/j.jelectrocard.2024.153782. Epub 2024 Aug 22.

Abstract

Background: Premature ventricular contractions (PVCs) are common arrhythmias with diverse clinical implications. This retrospective study aimed to evaluate the efficacy of medical treatments using various clinical, imaging, and electrocardiographic parameters in patients with idiopathic PVCs.

Methods: A total of 1051 patients with idiopathic PVCs were retrospectively analyzed. Patients were categorized into three groups based on treatment response: beta-blocker (BB) responders (479 patients), calcium-channel blocker (CCB) responders (335 patients), and class 1c antiarrhythmic (AA) responders (237 patients). Clinical, imaging, and electrocardiographic data were collected and analyzed to assess the factors influencing treatment response.

Results: Age, left ventricular ejection fraction (LVEF), PVC QRS duration, CI variability, and multiple PVC morphologies were identified as significant factors affecting treatment response. Older age and lower LVEF were associated with better response to BB treatment, whereas CCB responders showed narrower QRS complexes. BB responders also exhibited higher CI variability, possibly linked to automaticity mechanisms. Moreover, the BB responder group had a higher frequency of multiple PVC morphologies.

Conclusion: These findings emphasize the importance of tailored treatment approaches based on individual patient characteristics.

Keywords: Arrhythmia management; Multiple PVC morphologies; PVC QRS duration; Premature ventricular contractions (PVCs); Treatment response.

MeSH terms

  • Adrenergic beta-Antagonists* / therapeutic use
  • Adult
  • Anti-Arrhythmia Agents / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Electrocardiography*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Retrospective Studies
  • Treatment Outcome
  • Ventricular Premature Complexes* / drug therapy
  • Ventricular Premature Complexes* / physiopathology

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Calcium Channel Blockers